US 12,325,739 B2
Bispecific SARS-CoV-2 antibodies and methods of use
Aaron Sato, Burlingame, CA (US)
Assigned to Twist Bioscience Corporation, South San Francisco, CA (US)
Filed by Twist Bioscience Corporation, South San Francisco, CA (US)
Filed on Jan. 3, 2023, as Appl. No. 18/149,593.
Claims priority of provisional application 63/296,087, filed on Jan. 3, 2022.
Prior Publication US 2023/0257448 A1, Aug. 17, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/10 (2006.01); A61K 39/00 (2006.01); A61P 31/14 (2006.01)
CPC C07K 16/1003 (2023.08) [A61P 31/14 (2018.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A bispecific antibody or an antibody fragment thereof, comprising at least two binding domains to a spike glycoprotein or a receptor of the spike glycoprotein:
a first binding domain of the at least two binding domains comprising a first variable domain, heavy chain region (VH), wherein the first VH region comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, and wherein (i) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 1; (ii) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 2; and (iii) an amino acid sequence of CDRH3 as set forth in SEQ ID NO: 3; and
a second binding domain of the at least two binding domains comprising a first variable domain, heavy chain region (VH), wherein the first VH region comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, and wherein (i) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 4; (ii) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 5; and (iii) an amino acid sequence of CDRH3 as set forth in SEQ ID NO: 6.